A nationwide cohort study suggests clarithromycin-based therapy for Helicobacter pylori eradication is safe in patients with stable coronary heart disease and subsequent peptic ulcer disease

Table 4 Adjusted hazard ratio (aHR) of study outcomes associated with the duration of clarithromycin prescription

	Overall mortality aHR* (95% CI)	Cardiovascular mortality aHR* (95% CI)	Cardiovascular morbidity aHR^# (95% CI)
Nonusers (n = 4070)	1 (reference)	1 (reference)	1 (reference)
≦ 7 days (n = 2273)	1.21 (1.02–1.43)	0.90 (0.50–1.62)	0.92 (0.77–1.10)
> 7 days (n = 1297)	0.81 (0.62–1.05)	1.13 (0.37–3.43)	0.99 (0.75–1.31)

HR hazard ratio, CI confidence interval
*Adjusted for all covariates (age per year, sex, comorbidity, Charlson comorbidity index, number of medical visits, and drugs use) listed in Table 1
^#Adjusted for all covariates (age per year, sex, comorbidity, Charlson comorbidity index, number of medical visits, and drugs use) listed in Table 1 and competing mortality

ISSN: 1471-230X